CD38 Therapeutics

CD38 Therapeutics is a biotechnology company focused on the development of small molecule modulators of CD38, an enzyme central to NAD+ metabolism and intracellular calcium signaling. The company was founded by Dr. Hon-Cheung Lee, a pioneer in the field who is credited with discovering the enzymatic functions of CD38. Their therapeutic strategy involves inhibiting CD38 to prevent the depletion of NAD+, thereby addressing various age-related and metabolic diseases. CD38 Therapeutics aims to translate decades of basic research into clinical applications for conditions like obesity, diabetes, and chronic inflammation. The company's approach leverages deep expertise in the structural biology and biochemistry of the CD38 protein to design potent and selective therapeutic agents.